Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective study-Reference-Cited by-同舟云学术

Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective study

Published:2024-05-20 Issue:8 Volume:29 Page:1191-1197
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Hara Shuhei^ORCID,Mori Keiichiro,Fukuokaya Wataru,Tomomasa Naoya,Oguchi Takahiro,Takahashi Yusuke,Saito Shun,Katami Jun,Sano Takayuki,Kadena Soushi,Hashimoto Masaki,Yata Yuji,Nishi Eriko,Suhara Yushi,Takamizawa Shigeyoshi,Kurawaki Shiro,Suzuki Hirotaka,Miyajima Keiichiro,Iwatani Kosuke,Urabe Fumihiko,Ito Kagenori,Yanagisawa Takafumi,Tsuzuki Shunsuke,Shimomura Tatsuya,Kimura Takahiro

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10147-024-02548-6.pdf

Reference23 articles.

1. Siegel RL, Miller KD (2020) Jemal A (2020) Cancer statistics. CA Cancer J Clin 70(1):7–30. https://doi.org/10.3322/caac.21590

2. Kluth LA, Shariat SF, Kratzik C et al (2014) The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy. World J Urol 32(3):669–676. https://doi.org/10.1007/s00345-013-1157-5

3. Sternberg CN, Fizazi K, Saad F et al (2020) Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 382(23):2197–2206. https://doi.org/10.1056/NEJMoa2003892

4. Smith MR, Saad F, Chowdhury S et al (2021) Apalutamide and overall survival in prostate cancer. Eur Urol 79(1):150–158. https://doi.org/10.1016/j.eururo.2020.08.011

5. Fizazi K, Shore N, Tammela TL et al (2020) Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med 383(11):1040–1049. https://doi.org/10.1056/NEJMoa2001342

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative real-world study of apalutamide and darolutamide in Japanese patients with non-metastatic castration-resistant prostate cancer;2025-05-07

2. Real-world trends in the use and outcomes of novel androgen receptor signaling inhibitor therapy in patients with non-metastatic castration-resistant prostate cancer: A multicenter retrospective study;2025-05-07

3. Real-world clinical usage and efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer: a multi-institutional study in the CsJUC;Japanese Journal of Clinical Oncology;2025-02-02

4. Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter study;The Prostate;2024-10-17